Enhancing Antibody Therapeutics Through Precision Glycoengineering

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a critical mechanism in antibody therapeutics, enabling the immune system to eliminate cancerous or infected cells. ADCC activity is heavily dependent on glycan patterns, particularly Fc fucosylation levels. Even a 1 percent change in affucosylation makes a significant difference for ADCC. This underscores the immense therapeutic potential of glycosylation control, although replicating and optimizing glycan patterns remains a significant challenge in antibody development for researchers, biopharma companies and contract development and manufacturing organizations (CDMOs).

This webinar will explore how glycoengineering solutions are transforming antibody development by enabling precise control of glycan profiles to optimize ADCC activity. Attendees will gain insights into how innovative technologies streamline workflows, maintain productivity and meet the challenges of scalable production processes. The session will also highlight how these advancements can accelerate the development of biosimilars and next-generation antibody therapeutics.

A major advantage of these technologies is their ability to meet diverse development needs. Biosimilar developers can precisely match originator glycoprofiles to ensure regulatory compliance and therapeutic equivalence, while innovators can use precise glycosylation control to design next-generation antibodies with enhanced functionality. These versatile solutions enable the production of afucosylated antibodies to boost ADCC activity or fully fucosylated antibodies for antibody-drug conjugates (ADCs).

GlymaxX® technology exemplifies the impact of glycoengineering. By enabling up to 99 percent afucosylation, it significantly enhances ADCC activity. Its unique ability to adjust fucosylation levels offers unparalleled flexibility, allowing biopharma companies to produce innovative and potent therapeutics. This proven technology has been applied in late-stage clinical trials and contributed to the FDA approval of antibodies such as zanidatamab and zenocutuzumab.

Join this webinar to discover how precision glycoengineering can help overcome glycan modulation challenges, optimize ADCC and unlock the full potential of antibody portfolios. Register today to learn how these advancements improve therapeutic outcomes and streamline development processes.

Speaker

Dr. Volker Sandig, Chief Scientific Officer, ProBioGen

Dr. Volker Sandig has been part of ProBioGen since 2000. In that year, he initiated the company’s cell line development program, which resulted in the unique CHO.RiGHT® platform for protein production. He is the co-inventor of our key technologies, including the AGE1 designer cell lines, GlymaxX® and DirectedLuck®. His current work aims to modernize viral vector manufacturing and establish new platforms for RNA delivery. This includes customized design of suspension cell lines for viral vaccines as well as packaging and producer cell lines for gene therapy vectors. For his innovation and contribution to the field of animal cell culture technology, he received the inaugural 2019 ESACT Innovation Award.

Prior to joining ProBioGen, he led a research group at Merck Research Laboratories, USA, focusing on the development of manufacturing systems for gutless adenoviruses and vectored vaccines. Dr. Volker holds a medical degree and received his doctorate in molecular biology from the Humboldt University of Berlin, Germany.

Message Presenter